Gastroenterology and Hepatology: Disease Burden, Care Access and Industry Implications

Summary

Gastroenterology and hepatology covers digestive and liver disease, from colorectal screening and endoscopy to viral hepatitis treatment, cirrhosis and acute liver failure. The latest available data show a large burden. Liver disease causes over two million deaths a year ², cirrhosis caused more than 1.32 million deaths ³, and an estimated 1.3 billion people live with steatotic liver disease ¹. Progress against viral hepatitis is uneven. Only 15% of 167 countries met the hepatitis C mortality target ⁷, and WHO says current rates are insufficient for elimination targets ⁴. Colonoscopy waiting times vary widely by system, and the evidence on harm from delay is mixed ⁸⁹¹⁰. The main risks are stalled elimination, uneven treatment access, weak data quality ¹¹ and workforce constraints that the pack does not quantify. The outlook points to rising demand from metabolic liver disease, a push toward primary care integration ⁴ and greater need for reliable data before investment or policy decisions.

Key findings

1. 1

   Metabolic liver disease is the fastest-growing concern in the pack

   An estimated 1.3 billion people were living with MASLD in the latest estimate, with a projected 42% rise ¹. The estimate is an estimate and the projection is a forecast. Methods differ across sources, so the figures are not directly comparable.

   Confidence: Medium
2. 2

   Hepatitis B and C still drive most hepatitis deaths, and elimination is off track

   Hepatitis B and C together account for 95% of hepatitis-related deaths worldwide ⁴. WHO reports a 32% decline in new hepatitis B infections and a 12% fall in hepatitis C-related deaths, but states that current rates are insufficient to meet elimination targets ⁴.

   Confidence: High
3. 3

   Hepatitis C elimination targets are largely unmet across countries

   Only 15% and 14% of 167 countries and territories met the hepatitis C mortality and incidence targets, respectively ⁷. The United States showed 43% hepatitis C treatment coverage in the same analysis ⁷. These figures come from a conference presentation reported by a news outlet, so they are not peer-reviewed.

   Confidence: Medium
4. 4

   Evidence on colonoscopy waiting times is mixed and setting specific

   A US single-institution study reported a mean wait near six months with no later cancer stage at diagnosis ⁸. A Canadian indicator links waits over six months after a positive fecal test to reduced screening benefit ⁹. A nationwide French study found no evidence that waits of one to three months worsen outcomes ¹⁰. These findings do not establish a single safe threshold.

   Confidence: Qualitative
5. 5

   Data quality and workforce capacity are the main evidence gaps

   A first EU/EEA data collection found major problems with data completeness and quality ¹¹. The pack contains no verified workforce counts, market size, reimbursement data or digital adoption figures for this specialty, so these areas cannot be quantified here.

   Confidence: High

1Industry definition and scope

This report covers gastroenterology and hepatology: diseases of the digestive tract and liver, including colorectal cancer screening and follow-up colonoscopy, viral hepatitis, steatotic liver disease, cirrhosis and acute liver failure ²³⁵. The pack does not define commercial market boundaries for drugs, devices, endoscopy services or hospital care. The report therefore treats the field as a care and disease-burden system rather than a single revenue market.

Geographic scope is global, with national examples from the United States, Canada, Australia, France and the European Union and European Economic Area (EU/EEA). Reporting uses the latest available data. Sources use different baselines, definitions and methods, so figures are not restated to a common year and should not be compared directly.

Key terms: steatotic liver disease is the broader term used in recent reporting, and MASLD refers to metabolic dysfunction-associated steatotic liver disease. Older reviews use NAFLD for a similar concept, and their prevalence figures differ ¹¹². The report segments the field into screening and diagnostics, viral hepatitis, metabolic liver disease, and cirrhosis and acute liver failure.

Scope is set by the course subject and by the sources available in the pack.

2Market size, structure and value chain

The pack contains no verified global market size, revenue or growth figures for gastroenterology and hepatology drugs, devices or endoscopy services. Any statement about commercial scale would be unsupported, so it is not made here.

Burden indicators give a sense of scale. Liver disease causes over two million deaths a year, about 4% of all deaths ². Cirrhosis caused more than 1.32 million deaths in the latest period ³, and the prevalent cases of compensated cirrhosis were about 112 million, up from 65.9 million in an earlier period ³. Acute liver failure has an estimated incidence slightly above one case per million population per year ². These are estimates of need, not spending.

The care pathway runs from screening or case finding, through diagnostic testing and specialist assessment, to treatment and surveillance. For colorectal screening, a positive fecal test leads to follow-up colonoscopy ⁹¹⁰. WHO urges integrating hepatitis services into primary care ⁴, which would shift part of the value chain toward general practice. Stakeholders include primary care clinicians, specialists, public health programs, laboratories, hospitals and suppliers. Revenue models and reimbursement arrangements are not documented in the pack.

• Liver disease deaths More than 2 milliondeaths per year Observed Global, Latest available data [2]

Indicators come from different years and methods and are shown side by side for orientation only.

3Customers, demand and adoption

End users are people with digestive or liver disease, their families and the clinicians who manage them. Demand is shaped by the size of the at-risk population and by how well services reach people. Men carry a larger share of the burden in some measures: among male cirrhosis deaths, alcohol-related liver disease and hepatitis C each accounted for about a quarter or more ³. About one in three liver-related deaths occur among females ², so the pack does not support a single sex-based pattern.

Demand drivers include rising metabolic liver disease. Authors in one review describe a 25% prevalence of non-alcoholic fatty liver disease in many population groups, and express concern that no effective controls for excess alcohol and obesity have yet been introduced ¹². The WHA has recognized steatotic liver disease as a growing contributor to noncommunicable disease burden ¹.

Adoption and access show gaps. The US showed 43% hepatitis C treatment coverage in one analysis ⁷. In a subset of profiled countries, reported diagnostic and treatment rates were 90.6% and 92.8% ⁶. Purchasing criteria, patient preferences and payer decisions are not documented in the pack, so changing expectations cannot be assessed directly.

• Hepatitis C treatment coverage 43percent Observed United States, Latest available data [7]

Coverage figures come from a single analysis and may not reflect current national program data.

4Competitive landscape and key players

The pack names no commercial companies in gastroenterology or hepatology, so comparable company examples are limited. Comparison therefore rests on provider and program types: national programs, provincial systems, a single US institution and national study or reporting bodies ⁵⁸⁹¹⁰.

Egypt is the first country reported to reach gold tier status on the path to hepatitis C elimination ⁵. Canadian provincial jurisdictions reduced colonoscopy wait times in the later period compared with the earlier one ⁹. A single US institution reported long waits for surveillance colonoscopy while keeping cancer stage at diagnosis unchanged ⁸. These programs differ in scale, governance and data, so they are not directly comparable.

Public and private providers cannot be compared with verified data. The pack contains no verified public versus private comparison of waiting times, outcomes or costs for endoscopy or hepatology care . Provider concentration and market share are also not documented.

Competitive pressure appears mainly as regulatory and workforce limits on who may treat. In 12 of 33 profiled countries and territories (36%), prescribing authority for non-specialists is partly or fully restricted ⁶. This keeps treatment with specialists and may limit access where specialist numbers are low.

Interpretation of competitive pressure is the writer's, based on prescribing-restriction data.

5Technology, operations and workforce

Established practice includes fecal testing followed by colonoscopy for screening follow-up, and antiviral treatment for hepatitis B and C ⁹⁴. Emerging approaches such as AI-assisted endoscopy and telehepatology are discussed in general terms in the field, but the pack contains no verified adoption figures for them . Their uptake cannot be quantified here.

Operations are shaped by waiting times. The US single-institution study reported a mean wait near six months for screening or surveillance colonoscopy, with no later cancer stage at diagnosis ⁸. Guidelines cited in that study recommend a maximum wait of two months for diagnostic colonoscopy and six months for screening colonoscopy ⁸. Australian reporting gives a median of 62 days from a positive screening test to colonoscopy ¹⁰.

Workforce capacity is not quantified. The pack contains no verified counts of hepatologists, gastroenterologists or endoscopists per population . The restriction on non-specialist prescribing in 36% of profiled countries ⁶ is a clear constraint, and WHO's push to integrate services into primary care ⁴ implies a training and staffing need. Productivity and skills data are not available.

Workforce conclusions are qualitative because no staffing data were verified.

6Regulation, standards, risk and sustainability

Elimination frameworks in the EU/EEA define elimination as a 65% reduction in hepatitis-related deaths and a 90% reduction in new chronic hepatitis B and C infections, measured against a baseline ¹¹. The pack does not state whether these targets are legally binding. They should be treated as policy targets unless the governing EU instrument says otherwise. WHO hepatitis elimination targets are international policy goals, and the pack does not state any binding legal status for them ⁷⁴.

Screening standards are set by guidelines. The US guideline cited in one study sets maximum waits of two months for diagnostic colonoscopy and six months for screening colonoscopy ⁸. Canada's indicator treats waits over six months after a positive fecal test as reducing screening benefit ⁹. These are standards and indicators, not binding national law in the pack.

Risks include data quality, uneven access and disease drivers that remain unmanaged. The EU/EEA first data collection found major problems with completeness and quality ¹¹. Authors note that no effective controls have yet been introduced for excess alcohol consumption and obesity ¹². Privacy, ethics and safety rules for digital and AI tools are not covered in the pack, so no conclusion is drawn on them. This report does not provide medical, legal or engineering advice.

Legal status is stated only where the pack supports it. Otherwise the instrument is described as a policy target or guideline.

7Challenges, opportunities and case examples

The main constraints are stalled elimination progress, uneven treatment access and long or variable waits. WHO states current rates are insufficient for elimination targets ⁴, and only 15% of 167 countries met the hepatitis C mortality target ⁷. Prescribing restrictions and data gaps add further constraints ⁶¹¹.

Opportunities include primary care integration ⁴ and the policy learning available from countries that have progressed. Egypt is reported as the first country to reach gold tier status on the path to hepatitis C elimination ⁵. A nationwide French study found no evidence that waits of one to three months after a positive FIT worsen outcomes ¹⁰, which, if confirmed, could ease pressure on capacity. One study is not enough to set policy.

Three case examples illustrate the range. Egypt shows a national program reaching a stated elimination milestone ⁵. Canadian provinces show that waits can be reduced over time through jurisdiction-level indicators ⁹. A US institution shows that long waits can coexist with unchanged cancer stage at diagnosis in one setting ⁸. None of these examples provides cost or revenue data.

• Countries meeting the hepatitis C mortality target 15percent of 167 countries and territories Observed Global (167 countries and territories), Latest available data [7]

Case examples are drawn from the pack only and are not presented as a representative sample.

8Outlook and strategic implications

Near term, demand is likely to keep rising from metabolic liver disease, given the estimated 1.3 billion people with steatotic liver disease and the projected 42% rise ¹. This is a forecast, and its method may differ from other estimates. Hepatitis B and C remain major drivers of hepatitis deaths ⁴, so screening and treatment access will stay central.

Medium term, the main uncertainty is whether elimination progress can accelerate. WHO's call to integrate services into primary care ⁴ and the EU/EEA monitoring approach ¹¹ suggest a policy direction, but the pack gives no evidence of the scale of investment needed. Waiting time policy will depend on whether delays are harmful, and the current evidence is mixed ⁸⁹¹⁰.

Implications for stakeholders: policymakers need reliable data before setting targets ¹¹; providers should track waiting times against published standards ⁸⁹; suppliers and investors need market data that the pack does not contain, so commercial decisions should rest on additional sources; clinicians and programs should test primary care models against the prescribing constraints in ⁶.

Outlook is qualitative. No quantified market forecast is available in the pack.

9Conclusion

The burden of liver and digestive disease is large and, for metabolic liver disease, rising ¹². Viral hepatitis elimination is off track ⁴⁷. The most defensible takeaways are that access and data quality are the binding constraints, and that commercial sizing cannot be done from this pack.

Central assessment is the writer's interpretation of sourced evidence.

How this was built

Sources

1. 1

   Advancing liver health in a shifting global landscape

   Nature Reviews Gastroenterology & Hepatology Peer-reviewed

   nature.com
2. 2

   Global burden of liver disease: update

   Journal of Hepatology Peer-reviewed

   journal-of-hepatology.eu
3. 3

   The global, regional, and national burden of cirrhosis by cause in 195 countries and territories

   GBD Cirrhosis Collaborators, The Lancet Gastroenterology & Hepatology Peer-reviewed

   thelancet.com
4. 4

   Global Hepatitis Report and WHO call for stepped-up action on viral hepatitis

   UN News (reporting on the World Health Organization Global Hepatitis Report) News report

   news.un.org
5. 5

   Global hepatitis report

   World Health Organization Official statistics

   globalhep.org
6. 6

   A global report on national policies, programs, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles

   Coalition for Global Hepatitis Elimination (published in Health Policy) Peer-reviewed

   sciencedirect.com
7. 7

   Global progress toward WHO hepatitis C elimination targets

   Coalition for Global Hepatitis Elimination, presented at AASLD The Liver Meeting (reported by EATG) News report

   eatg.org
8. 8

   Wait Time for Colorectal Cancer Screening and Diagnosis

   Clinical and Translational Gastroenterology (US study, PMC archive) Peer-reviewed

   pmc.ncbi.nlm.nih.gov
9. 9

   Partnership Against Cancer: Wait time to follow-up colonoscopy indicator

   Partnership Against Cancer (Canada) Industry association

   partnershipagainstcancer.ca
10. 10

    Can colonoscopies wait longer? (BMJ Gut study summary)

    Oncology Republic (reporting on a BMJ Gut study) News report

    oncologyrepublic.com.au
11. 11

    Monitoring progress towards elimination of hepatitis B and C in the EU/EEA

    European Center for Disease Prevention and Control and collaborators (PMC) Peer-reviewed

    ncbi.nlm.nih.gov
12. 12

    Hepatology through the crystal ball

    Institute of Hepatology, London; King's College London (Hepatology International) Peer-reviewed

    ncbi.nlm.nih.gov